Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.91) per share which missed the ana

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Th

Expected gross proceeds anticipated to extend the Company's cash runway to the end of calendar 2028

FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Cli

FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Cli

Grace Therapeutics, Inc. (NASDAQ: GRCE - Get Free Report)'s share price fell 2.5% on Wednesday. The

Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analy

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 ST

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litiga

GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall

LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigat

ATLANTA, June 03, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Grace Thera

Grace Therapeutics is rated a Speculative Buy with a $4 price target, implying 57% upside after a sh

LOS ANGELES--(BUSINESS WIRE)---- $GRCE--GRCE Investors Have Opportunity to Join Grace Therapeutics,

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics,

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

TD Cowen analyst Stacy Ku maintains Grace Therapeutics (NASDAQ:GRCE) with a Buy and lowers the pr

Grace Therapeutics Inc. (NASDAQ:GRCE) shares are down during Friday's premarket session following a

Grace Therapeutics stock drops after FDA flags NDA issues for GTx-104; CMC concerns weigh despite no

Grace ​Therapeutics said ‌on ​Thursday ​the U.S. ⁠Food ​and Drug ​Administration declined ​to ​appro

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, an

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, an

The STRIVE-ON Trial results will be presented as a poster on April 21, 2026. Details are as follows:

PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace T

Grace Therapeutics, Inc. (NASDAQ: GRCE - Get Free Report) was the recipient of a significant increas

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.14) per share which beat the analy

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.06) per share which beat the analy